PDE5A and benign prostatic hyperplasia: ABs α-1 blockers, PDE5-Is phosphodiesterase 5 inhibitors, BPH benign prostatic hyperplasia, LUTS lower urinary tract symptoms, ED erectile dysfunction, OR odds ratio, WMD weighted mean difference, CI confidence interval, IPSS International Prostate Symptom Score, PVR postvoid residual urine, Qmax maximum flow rate, IIEF International Index of Erectile Function, QoL quality of life, AEs adverse effects.